Lynparza (olaparib) for the Treatment of BRCA-mutated Advanced Ovarian Cancer - Clinical Trials Arena
Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design | Future Oncology
Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evid | OTT
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative Metastatic Breast Cancer
PARP Inhibition for Ovarian Cancer - ppt download
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer - European Journal of Cancer
VisualAbstract: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer | 2 Minute Medicine
PARP Inhibition for Ovarian Cancer - ppt download
Clinical Trials of PARP inhibitors in ovarian cancer | Download Table
PARP inhibitors: Choosing what to use in epithelial ovarian cancer
Breakthrough from PAOLA1 GINECO/ENgOT-ov25 trial
JCM | Free Full-Text | Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study | HTML
SOLO-1 Phase 3 Trial Demonstrates LYNPARZA® (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer | Business Wire
Platinum-Sensitive Recurrent Disease - PARPi in Ovarian Cancer - Module - PARPi in Ovarian Cancer - Oncology - Clinical Care Options
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
Platinum-Sensitive Recurrent Disease - PARPi in Ovarian Cancer - Module - PARPi in Ovarian Cancer - Oncology - Clinical Care Options
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer - Annals of Oncology
Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis | Scientific Reports
Olaparib Maintenance Reduces the Risk of Recurrence in Newly
Frontiers | PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials | Oncology
A trial of olaparib for ovarian cancer that has come back (MOLTO) | Cancer Research UK
Completed clinical trials of olaparib combinations with other agents in... | Download Scientific Diagram
Enrolling Clinical Trials: Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer - Penn Medicine
